BiomX

Historical price data

BiomX is a clinical-stage biotechnology company with a mission to develop precisely targeted, engineered bacteriophage therapies for chronic diseases linked to specific harmful bacteria. Its core achievement is building a proprietary discovery and synthetic biology platform to create optimized phage cocktails, advancing multiple candidates into clinical trials for acne, Crohn's disease, and colorectal cancer. The company's strategy focuses on validating its platform in high-value therapeutic areas with clear bacterial drivers, aiming to establish a new class of microbiome-sparing anti-infectives. BiomX faces the dual challenge of proving clinical efficacy in complex diseases and navigating the nascent regulatory pathway for phage-based biologics.

A proprietary platform for discovering, rationally engineering, and optimizing natural bacteriophages into defined, synergistic therapeutic cocktails designed to precisely target pathogenic bacteria while preserving the microbiome.

BiomX competes with a small number of clinical-stage phage therapy companies, broader microbiome modulators (e.g., live biotherapeutics), and entrenched standard-of-care drugs. Its key differentiation is its platform for engineering optimized, targeted phage cocktails for chronic microbiome-linked diseases.